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Specific conformational changes in the envelope glycoprotein gp120 of the human immunodeficiency virus type-1 (HIV-
1) may be critical for eliciting a broadly neutralizing immune response against primary virus isolates. Since the interaction
of gp120 with its receptor, CD4, induces conformational perturbations in both molecules, gp120-CD4 complexes should
present unique immunogenic features that may include novel epitopes for broadly neutralizing antibodies. To test this
hypothesis, we raised polyclonal antiserum against covalently crosslinked gp120–CD4 complexes in a goat and examined
the ability of the anti-complex antibodies to neutralize primary and laboratory-adapted HIV-1 isolates. In cell-free neutraliza-
tion assays with HIV-1MN , the antiserum demonstrated the ability to neutralize primary virus more effectively than the
laboratory-adapted isolate. The neutralizing capacity of the anti-complex serum extended to primary isolates from distant
genetic clades A, D, and E, although the degree of neutralization was found to vary among the clades. The neutralizing
activity of the serum was composed of two components. The first component included anti-CD4 antibodies that recognized
epitopes outside the gp120 binding site; the second was independent of CD4 reactivity and was retained after removal of
cell surface anti-CD4 reactivity by repeated absorption with CD4-positive cells. These results demonstrate that gp120–CD4
complexes can elicit a unique polyclonal antibody response that is relevant to the neutralization of primary isolates of
HIV-1. q 1996 Academic Press, Inc.
Current efforts in developing an effective vaccine ability to elicit a strong humoral response against neu-
tralizing epitopes that are conserved among diverse HIV-against the human immunodeficiency virus type-1 (HIV-
1) have been focused on the envelope glycoproteins of 1 strains likely to be encountered in vivo. Unfortunately,
such expectations have not been met since to date thethe virus. One of these antigens, gp120, has been the
subject of considerable research interest due to its neutralizing responses elicited in humans and nonhu-
involvement in the initial stage of the HIV-1 life cycle as man primates with various preparations of purified re-
well as its ability to elicit a virus-neutralizing immune combinant gp120 have been restricted to the isolate used
response in an immunized host (1–5). A majority of HIV- for immunization and those closely related to it (16–18).
1-infected individuals develop an anti-gp120 immune re- More important, such responses are largely ineffective
sponse, which neutralizes HIV-1 infection (4–7). While against primary isolates that are derived from infected
the role played by these antibodies in influencing HIV-1 individuals and/or cultured exclusively in peripheral
pathogenesis is not clearly understood, an overall strong blood mononuclear cells (PBMC) (19, 20).
neutralizing antibody response is often associated with Despite these problems it is possible that gp120 could
good clinical outcome (4). Moreover, a number of human be used as a vaccine immunogen if its structure could
monoclonal antibodies have been shown to neutralize be perturbed in a manner that could enhance the expo-
diverse HIV-1 isolates under a variety of conditions (8– sure of neutralizing epitopes that are likely to be encoun-
15). The success of any vaccine approach utilizing gp120 tered during natural infection. One way to induce such
requires that preparations of the antigen maintain the an effect is through complex formation with the CD4 re-
ceptor. It has been well documented that the interaction
of gp120 with CD4 causes significant alterations in the
1 Current address: Institute of Human Virology, Medical Biotechnol- conformations of both molecules (21–25). Several lines
ogy Center, University of Maryland Biotechnology Institute, University
of evidence suggest that CD4-induced structuralof Maryland, Baltimore, MD 21201.
changes can enhance the immunogenicity of conserved2 To whom correspondence and reprint requests should be ad-
dressed. Fax (301) 468-9466. gp120 epitopes (26–31). First, immunization with gp120–
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CD4 complexes enhances the immunological response
against conserved neutralizing epitopes within the CD4
binding site on gp120 (29). Second, human monoclonal
and monospecific neutralizing antibodies recognize a
discontinuous epitope on gp120 that exhibits enhanced
exposure following CD4 binding (28, 30). Recently, we
have shown that covalently crosslinked gp120–CD4
complexes elicit monoclonal antibodies against a
unique, conformation-dependent epitope on the gp120
molecule that is exposed following interaction with CD4
(31). These results indicated that the crosslinked com-
plex may represent an immunogen that can elicit a neu-
tralizing polyclonal immune response with novel specific-
ities.
In order to examine this possibility an anti-complex
response was generated by immunizing a goat (desig-
nated as goat 69) with crosslinked gp120–CD4 com-
plexes. The response was first analyzed by ELISA with
either CD4, gp120, or the gp120–CD4 complexes ad-
sorbed to the solid phase. As shown in Fig. 1A, serum
samples collected at various times from goat 69 during
the inoculation schedule exhibited reactivities with all of
the antigens tested, which in every case reached maxi-
mum levels after five inoculations. The highest levels of
seroreactivity were most pronounced with complexes;
the degree of reactivities with both CD4 and gp120 were
lower. Notably, antibody titers uniformly declined after
five inoculations but remained at a relatively constant
level after seven inoculations.
In syncytium blocking assays (32), all of the serum
samples neutralized both of the laboratory-adapted iso-
lates HIV-1IIIB and HIV-1MN . The changes in the syncytium
FIG. 1. Reactivities of antibodies raised against gp120-CD4 complex.blocking titers (Fig. 1B) over the course of the immuniza-
Covalently crosslinked complexes of viral gp120 (46) and CD4 (duPont)tion protocol resembled the trend observed with the other
were prepared using Bis[sulfosuccinimidyl] suberate (BS3) (Pierce) as
antibody reactivities (Fig. 1A) with the maximum syncy- described (31). Immunization of goat 69 was initiated by inoculation
tium blocking titer (1:160) observed after five inocula- with 200 mg of the crosslinked complex in complete Freund’s adjuvant.
After 3 weeks, the animal was immunized six times at biweekly intervalstions. When the experiments were repeated with serum
with 100 mg of complex in incomplete Freund’s adjuvant. After a 4-from an animal (goat 58) immunized with gp120 alone
week rest the animal received four additional inoculations at biweeklyonly the syncytium formation induced by HIV-1IIIB was intervals. (A) Samples were tested simultaneously at twofold serial
inhibited (data not shown). Serum from another animal dilutions in ELISA with gp120 (l), CD4 (j), or gp120-CD4 complex (m)
(goat 70) immunized with gp120 crosslinked to the lectin as described elsewhere (31). Titers were determined as the highest
dilution of immune serum producing ELISA values (A450 nm) greatersuccinyl Con A (23) with BS3 failed to inhibit syncytium
than or equal to two times the level of binding detected with a corre-induced by either isolate tested (data not shown).
sponding dilution of preimmune serum. (B) Syncytium assays wereThe anti-complex serum was next examined for the
conducted by coculturing CEM cells with either H9/HIV-1IIIB (l) or H9/ability to neutralize the cell-free infection of PBMC by HIV-1MN (m) as described elsewhere (32, 46). The minimum serum
various HIV-1 isolates. A comparative analysis was first dilution tested was 1:20. Syncytia blocking titers were determined as
the dilution of serum producing ⁄90% inhibition of syncytia formationperformed with both primary and laboratory-adapted
relative to untreated samples. Preimmune serum had no inhibitory ef-forms of the strain HIV-1MN . The HIV-1MN isolate was
fect on syncytium formation relative to assays carried out in the ab-originally obtained from a pediatric AIDS patient and was
sence of goat serum.
maintained exclusively in PBMC (33). The laboratory-
adapted virus was obtained from the culture supernatant
of chronically infected H9 cells. Each virus was titered was assayed in parallel with the goat serum. Goat 69
immune serum samples were diluted in culture mediumusing PBMC to determine a 50% tissue culture infectious
dose (TCID50) (34). A pool of control neutralizing sera from and subjected to twofold serial dilutions in an equal dilu-
tion of preimmune serum so as to maintain a constantHIV-1-infected individuals (FDA-2; NIAID AIDS Research
and Reagent Program Repository, Rockville, MD) (35) level of goat serum in all assays. Similarly, FDA-2 human
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sera (35) was diluted in culture medium and subjected
to twofold serial dilutions in an equal dilution of normal
human serum. All serum samples were heat inactivated
before testing. Each serial dilution of test serum was
then mixed with virus and PHA-stimulated PBMC (2 1
105/well). After an 18-hr incubation at 377 the cells were
washed once with 150 ml of culture medium and fresh
medium containing respective dilutions of each test se-
rum was added to each well. After 96 hr, the cells were
washed extensively with culture medium and plated in
fresh medium without test serum. The extensive washing
reduced the residual human serum in the culture 1 1
106-fold, which in the case of FDA-2 sera represents a
concentration that does not interfere with the HIV-1 p24
antigen capture assay (data not shown). The levels of
infection in the assay supernatants were measured on
either Day 6 or 7 using an HIV-1 p24 antigen capture
ELISA (Organon Teknika). As shown in Fig. 2A, serum
samples from goat 69 collected after 5 and 11 inocula-
tions (designated as bleed 2 and bleed 7) were able to
neutralize 50 TCID50 of the primary HIV-1MN isolate at
serum dilutions of 1:320 and 1:160, respectively. Surpris-
ingly, the ability of the goat serum samples to neutralize
the same infectious dose of the laboratory-adapted iso-
late was significantly lower (1:80 for bleed 2 and 1:20 for
bleed 7). As described for these and other HIV-1 anti-
body-positive human sera (19, 20, 35) the FDA 2 sera
indicated the opposite trend and displayed a neutralizing
titer that was twofold higher with the laboratory-adapted
virus than with the primary virus (Fig. 2A). In contrast,
both goat 58 and goat 70 immune sera were unable to FIG. 2. Neutralization of diverse HIV-1 isolates by anti-complex goat
neutralize the primary HIV-1MN virus (data not shown). serum. Goat 69 bleed 2 and 7 serum samples and FDA-2 human sera
were tested for neutralization as described in the text. The minimumOverall, these results suggested that the crosslinked
serum dilutions tested were 1:20 and 1:100 with goat and human sam-complexes elicited a polyclonal neutralizing response
ples, respectively. Neutralization titers are expressed as the highestthat was significantly different from the typical anti-HIV
dilution of serum inhibiting infection⁄80% (ID80) or ⁄50% (ID50) relativeresponse in that it was most effective against primary to assays carried out with a 1:20 dilution of normal goat serum or a
HIV-1 isolates. Such results are distinct from what has 1:100 dilution of normal human serum as appropriate. The results
shown represent the mean value obtained from duplicate assays. (A)been observed with other gp120-based immunogens,
ID80 determined with primary ( 
) and laboratory-adapted (‹) HIV-1MN .which typically elicit antibodies that are effective against
(B) Neutralization titers (ID80 , ID50) of bleed 2 (j, 
) and bleed 7 (
  
  ,only laboratory-adapted virus isolates (16–20).
h) with HIV-1IIIB or with primary isolates from clades A, D, and E. AnTo further examine this property, the anti-complex infectious dose of 50 TCID50 was used in every case. The percentage
bleed 2 and bleed 7 samples were diluted in normal goat inhibition was determined as above and plotted against serum dilution.
The ID80 and ID50 was determined by extrapolation from the plot.serum as before and tested with the primary isolates
representing clades A, D (NIAID AIDS Research and Ref-
erence Reagent Program Repository, Rockville, Mary-
to be more effective against the clade D isolate thanland), or E and with the laboratory-adapted HIV-1IIIB iso-
against the isolates from clades A and E (Fig. 2B). More-late. As shown in Fig. 2B, the bleed 2 sample was able
over, the serum had no inhibitory effect on HIV-1IIIB infec-to neutralize all three primary isolates with an ID80 of
tion at the serum dilutions tested (Fig. 2B). This sug-1:28 for clades A and D and 1:20 for clade E. Similarly,
gested that the population of antibodies changed withthe corresponding ID50 was 1:38 for clades A and D and
repeated inoculation of the complex in such a way as to1:28 for clade E. Compared to the primary viruses, the
favor the neutralization of primary isolates. ContinuedHIV-1IIIB isolate, which served as the source of gp120
screening of a wider variety of isolates should provide aused in the complexes, was slightly more sensitive to
more accurate characterization of the cross-clade neu-neutralization by bleed 2; the ID80 and ID50 were 1:40
tralizing capacity of the anti-complex response.and 1:70, respectively (Fig. 2B). Notably, the neutralizing
capacity of bleed 7 differed from bleed 2, as it appeared In order to characterize the anti-complex immune re-
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sponse in greater detail, we tested the goat serum for
antibody specificities that might be plausible sources of
neutralizing activity. Since the serum contained high ti-
ters of anti-CD4 reactivity, we first tested for the presence
of antibodies against CD4 epitopes involved in gp120
binding. One such antibody, OKT4A, is known to inhibit
HIV-1 infection by blocking the interaction of gp120 with
CD4 (1–3). However, in flow cytometric analysis the anti-
complex serum (bleed 2) did not decrease the signal
produced by FITC-conjugated OKT4A monoclonal anti-
body when compared to what was detected in the pres-
ence of a nonspecific monoclonal antibody or the preim-
mune goat serum (data not shown). Similar results were
obtained with the bleed 7 sample (data not shown).
These results demonstrated that antibodies against the
OKT4A binding site, or other CD4 epitopes involved in
the initial step of the virus–cell interactions, were not
present at detectable levels in serum dilutions that effec-
tively neutralized HIV-1 (Figs. 2A and 2B). Consistent with
this interpretation, none of the serum samples collected
after inoculation with the complex had any inhibitory ef-
fect on the formation of gp120–CD4 complexes in solid
phase ELISA assays (data not shown).
It remained possible that the neutralizing activity of
anti-complex serum involved other anti-CD4 seroantibod-
ies which do not interfere in complex formation and in-
stead act at a postbinding event (36, 37). To examine this
possibility the anti-complex goat serum was subjected to
multiple rounds of absorption against CD4/ SupT1 cells
in order to remove antibodies directed against cell sur-
face CD4. The bleed 7 serum was selected for such
treatment since it already contained relatively lower titers
of anti-CD4 antibodies (Fig. 1A). Absorbed or unabsorbed
serum was then tested for binding to SupT1 cells and
for neutralization of primary HIV-1MN . As shown in Fig.FIG. 3. Neutralization of HIV-1 isolates by anti-complex serum after
removal of anti-CD4 reactivity. (A) Goat 69 serum was heat inactivated 3A, the absorption procedure produced a marked reduc-
at 577 for 30 min and diluted 1:20 in 3 ml of culture medium. The diluted tion in cell surface reactivities with SupT1 cells. At the
serum was incubated with 1 1 107 SupT1 cells by gently rocking for lowest dilution tested (1:20), the intensity of the signal
30 min at room temperature. Cells were then removed by centrifugation.
seen with the absorbed serum was only 16% of what wasThe supernatant was subjected to nine additional absorptions with the
observed with the unabsorbed serum. The cell surfacecells and then centrifuged at 100,000 g for 15 min to remove residual
cell debris. Neutralization of HIV-1MN infection by absorbed (m) or unab- reactivities detected with higher dilutions of the absorbed
sorbed serum (l) was tested as described in the text except that serum serum were negligible. Although the reduction in anti-
samples were maintained in the assay wells until 96 hr after infection CD4 binding was accompanied by a measurable de-
at which time half of the culture was removed and replaced with culture
crease in neutralization titers, a strict correlation be-medium without test serum. HIV-1 p24 levels were measured in all
tween the two reactivities was not apparent. Moreover,replicate wells and the mean was determined. Percentage inhibition
was calculated relative to the mean p24 level measured in replicate in the absence of anti-CD4 binding, the absorbed serum
assays containing preimmune goat serum. The results shown repre-
sent a typical experiment that was repeated several times with similar
results. Cell surface binding was determined by incubating SupT1 cells
(3 1 106) with multiple dilutions of absorbed (n), unabsorbed (s), or serum ( ) were tested in infectivity reduction assays with a fixed dilu-
preimmune serum in culture medium (100 ml) for 30 min at 47. The cells tion of immune serum or normal goat serum and different doses of
were then washed with PBS and incubated with FITC-conjugated rabbit virus as described in the text. Virus and the immune sera were preincu-
anti-goat antibody (Sigma) (1:80 dilution) in 100 ml PBS at 47 for 30 min bated at room temperature for 30 min before addition of PBMC. Assay
and analyzed by flow cytometry (31). The cell surface binding repre- cultures were incubated for 96 hr at which time each culture was
sents the mean log fluorescence intensity obtained from the analyses divided into two wells. Culture medium without test serum was then
of 10,000 accumulated events from which the signal obtained with the added to all wells. HIV-1 p24 levels were measured in all replicate
preimmune serum has been subtracted. (B) Samples of unabsorb- wells and the mean was determined. The results represent the mean
ed (‰) and cell absorbed (
  
  ) bleed 7 serum or normal goat p24 levels { standard error for all replicate assays.
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continued to neutralize cell-free infection (Fig. 3A), al- antibodies in the immunized host may not be detrimental
to the immune status of the animals (42–45). The resultsthough it was unable to block syncytium formation in-
duced by either HIV-1IIIB or HIV-1MN (data not shown). presented here showing a polyclonal anti-complex re-
sponse effective against primary HIV-1 isolates indicateThese results suggested that the anti-complex serum
contained two populations of neutralizing antibodies: one that crosslinked complexes warrant further investigation
in a relevant animal model.directed against CD4 that mediates both syncytium inhi-
bition and a portion of cell-free neutralization and a sec-
ond composed of antibodies not strictly CD4-directed. ACKNOWLEDGMENTS
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